The new brand reinforces the company’s commitment to the power of partnership and the infinite possibilities of scientific innovation
San Diego, California, October 26, 2021 – Crown Bioscience, a JSR Life Sciences company and leading CRO in preclinical and translational drug development services, today announced it has refreshed its corporate identity. The change represents a recognition that the company’s spectrum of scientific expertise, from early-stage research and discovery to preclinical and translational research has evolved at a rapid pace and a need to reposition. The rebranding launch coincides with the company’s fifteenth anniversary.
Armin Spura, PhD, Chief Executive Officer of Crown Bioscience stated, “We’re proud of Crown Bioscience’s innovations and accomplishments in our fifteen-year history of empowering our customers to improve human health. Recognizing the necessity for agility to accurately address our customers’ needs, but without ever compromising quality, our new brand reflects the core of who we are: the power of partnership and innovation to transform drug discovery and development.”
The rebrand comes in the wake of numerous investments and expansion across the business including the recent acquisition of OcellO BV in May of 2021. It is intended to better position the company as it continues its market leading growth trajectory.
- A focus on ‘The Power of Partnership’, that Crown Bioscience partners with customers and research institutions to fuel the infinite possibilities of drug discovery, and scientific advancement.
- A new visual identity, showcasing an infinity symbol, which reflects the shared journey of discovery, and symbolizes the company’s dedication to continuously meet and exceed customer needs. The mark also encapsulates the infinite possibilities that innovation, quality, expertise, and customer focus will create in the world of science and healthcare.“
- Our new brand is a living representation of our partnerships and the infinite possibilities for science and collaboration to transform the future of scientific discovery” said Gavin Cooper, Executive Director of Marketing, Crown Bioscience. “It reflects the shared journey that that we enter into with our customers, a journey that we hope will accelerate the advancement of new and novel therapies.”
As part of the rebrand, Crown Bioscience launched a new website, reflective of the new visual identity: https://www.crownbio.com
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biops...
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...
Crown Bioscience Enters Global Agreement with Shanghai Model Organisms Center
Crown Bioscience announces the completion of a global collaboration agreement with the Shanghai Model Organism Center (SMOC). This five-year agreement extends the existing partnership and will prov...
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.